Mephenamine tablets. Mefenamic acid-darnitsa

Mefenamic acid is a non-steroidal anti-inflammatory and anti-rheumatic drug used for diseases of the musculoskeletal system, mild and moderate pain, as well as fever.

pharmachologic effect

Mefenamic acid has anti-inflammatory, antipyretic and analgesic properties.

The anti-inflammatory effect of mefenamic acid is due to its ability to inhibit the synthesis of prostaglandins and serotonin, which take an important part in the processes of inflammation. The ability to reduce the production of prostaglandins and influence the thermoregulation center explains the antipyretic effect of mefenamic acid. The analgesic effect of the drug is due to its influence on the central and peripheral mechanisms of pain sensitivity.

Mefenamic acid can increase the activity of T-lymphocytes, which play a significant role in the functions of immune system, and stimulate the production of interferon, which suggests its anti-inflammatory effect. After oral administration, the maximum concentration of mefenamic acid in the blood can be observed after 2-4 hours. The half-life of the drug is 3 hours. About 67% of mefenamic acid is excreted in the urine, and the rest in feces.

Indications for use

Mefenamic acid, the instructions confirm, is effective for such inflammatory diseases of the musculoskeletal system as:

• rheumatism (a disease that affects the cardiovascular system and connective tissue);
• gout (a disease of the joints caused by the accumulation of uric acid in them);
• rheumatoid arthritis (destructive damage to large and small joints of the extremities);
• Ankylosing spondylitis (limited mobility of the spine and possible involvement in the inflammatory process of the lungs, kidneys, heart and other internal organs).

It is advisable to use mefenamic acid to eliminate pain in neuralgia, radiculitis, menstruation, childbirth, and cancer.

Mefenamic acid is also effective for mild or moderate headaches and toothaches, pain in muscles, joints, bones, pain during menstruation, febrile syndrome accompanying infectious and colds.

Instructions for use of mefenamic acid

Mefenamic acid is available in the form of a powder substance and tablets (250 mg or 500 mg). It is recommended to take the drug orally after meals with milk. Adults are usually prescribed 250-500 mg 3-4 times a day, while the maximum daily dose should not exceed 3 grams, the recommended daily dose after achieving a therapeutic effect is 1 gram.

Mefenamic acid for children 5-10 years old is prescribed in a single dose of 250 mg, and for children over 10 years old - 300 mg, the frequency of doses for these age groups– 3-4 times a day.

The instructions recommend taking mefenamic acid for 20-45 days, but if necessary, the course can be extended to 2 months or more.

Locally, mefenamic acid is used in the form of a 1% paste or 0.1-0.2% solution. The paste is recommended to be injected into periodontal pockets after 1-2 days (6-8 sessions), and applications should be made with an aqueous solution 1-2 times a day for ulcerative lesions of the oral mucosa.

Side effects

According to the instructions, mefenamic acid can provoke the manifestation of such undesirable effects as:

• gastrointestinal discomfort, indigestion, heartburn, nausea, loss of appetite, diarrhea, flatulence, constipation, gastrointestinal bleeding;
• increased blood pressure, disorder heart rate, peripheral edema;
• nonspecific inflammation of the kidneys, hematuria (the presence of blood in the urine in an amount exceeding the norm), albuminuria (protein excretion in the urine);
• bronchospasm, shortness of breath;
• drowsiness, blurred vision, general weakness, insomnia, nervousness;
• allergic skin reactions;
• with high concentrations in the blood - vomiting, convulsions, muscle twitching;
• with long-term use - impaired hematopoiesis, decreased hematocrit (the ratio of red blood cell volume to blood volume), hemolytic anemia (a disease caused by increased destruction of red blood cells).

Contraindications to the use of mefenamic acid

Mefenamic acid is not prescribed for hypersensitivity, peptic ulcer, inflammatory processes of the digestive tract, blood diseases and impaired kidney and liver function.

Mefenamic acid is contraindicated for children under 5 years of age and for pregnant and lactating women.

Additional Information

Mefenamic acid will be suitable for use for 3 years, provided it is stored in a dry and dark place where the air temperature does not exceed 250C.

Sincerely,

Attention! The information is provided for informational purposes only. This instruction should not be used as a guide to self-medication. The need for prescription, methods and doses of the drug are determined exclusively by the attending physician.

general characteristics

international and chemical names: mefenamic acid, N-(2,3-dimethylphenyl) anthranilic acid;

basic physical and chemical properties: tablets are flat-cylindrical, grayish-white in color with a slightly yellowish or greenish tint (marbling is allowed), odorless;

compound: 1 tablet contains mefenamic acid - 0.5 g;

Excipients: potato starch, methylcellulose, talc.

Release form. Pills.

Pharmacotherapeutic group

Nonsteroidal anti-inflammatory and antirheumatic drugs. ATS code M01A G01.

Pharmacological properties

Pharmacodynamics. Mefenamic acid-Darnitsa has anti-inflammatory, antipyretic and analgesic properties.
Affects phases (Phase- homogeneous, physically independent and detachable part complex system) exudation and proliferation (Proliferation(from lat. proles - offspring, offspring and fero - carry) - proliferation of body tissue through new formation (reproduction) of cells. Can be physiological (e.g. normal regeneration, proliferation of mammary gland cells during pregnancy and lactation) and pathological (e.g. tumors)) with inflammation. The mechanism of anti-inflammatory action is due to the ability to inhibit the synthesis mediators (Mediator- a substance that transfers excitation from the nerve ending to the working organ and from one nerve cell to another) inflammation (prostaglandins, serotonin (Serotonin- a derivative of the amino acid tryptophan. It is synthesized mainly in the central nervous system and chromaffin cells of the gastrointestinal tract. A mediator of nerve impulse transmission through a synapse. Neurons of the vertebrate brain, using serotonin as a mediator, are involved in the regulation of many forms of behavior, sleep processes, thermoregulation, etc. As a hormone, serotonin also regulates the motility of the gastrointestinal tract, mucus secretion, causes spasm of damaged blood vessels, etc. ), kinins (Kinins- substances with a wide range of biological activity. Kinins relax vascular smooth muscle, lower blood pressure, increase capillary permeability, cause painful sensations, contract or relax the smooth muscles of isolated organs) etc.), reduce the activity of lysosomal enzymes (Enzymes- specific proteins that can significantly accelerate chemical reactions, occurring in the body without being part of the final reaction products, i.e. are biological catalysts. Each type of enzyme catalyzes the transformation of certain substances (substrates), sometimes only a single substance in a single direction. Therefore, numerous biochemical reactions in cells are carried out by a huge number of different enzymes. Enzyme preparations are widely used in medicine), which take part in the inflammatory response. Mefenamic acid-Darnitsa stabilizes protein ultrastructures and cell membranes, reduces vascular permeability, uncouples oxidative phosphorylation, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation at the site of inflammation, increases resistance (Resistance- body stability, immunity to any external factors. In particular, nonspecific resistance is called means of innate immunity. The term is more often used in relation to microorganisms (the emergence of mechanisms of immunity to antimicrobial drugs, antibiotics) or plants (to diseases). In relation to humans and animals, the term immunity is more often used) cells and stimulates wound healing.
Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center. In the mechanism of analgesic action, along with the influence on the central mechanisms of pain sensitivity, a significant role is played by the local effect on the site of inflammation and the ability to inhibit the formation of algogens (kinins, histamine (Histamine- a derivative of the amino acid histidine. Contained in an inactive, bound form in various organs and tissues, it is released in significant quantities during allergic reactions, shock, and burns. Causes dilation of blood vessels, contraction of smooth muscles, increased secretion of hydrochloric acid in the stomach, etc.), serotonin).
Unlike most other non-steroidal anti-inflammatory drugs, Mefenamic acid-Darnitsa stimulates the formation of interferon.

Pharmacokinetics. After oral administration, mefenamic acid is quickly and fairly completely absorbed from the digestive tract. The maximum concentration in the blood is observed 2-4 hours after administration. The blood level is proportional to the dose. The equilibrium concentration (20 mcg/ml) is determined on the 2nd day of use (1 g 4 times a day).
Contacts albumins (Albumin- simple globular proteins contained in blood serum are determined in the laboratory during a biochemical blood test) blood. In the liver it forms metabolites by oxidation, hydrolysis, glucuronidation. Half-life (Half-life(T1/2, synonymous with half-elimination period) - the period of time during which the concentration of a drug in the blood plasma decreases by 50% from the initial level. Information about this pharmacokinetic indicator is necessary to prevent the creation of a toxic or, conversely, ineffective level (concentration) of the drug in the blood when determining the intervals between administrations) from the blood is about 3 hours. It is excreted from the body unchanged and in the form of metabolites mainly by the kidneys (67% of the dose), with feces (20-25%).

Indications for use

Mefenamic acid-Darnitsa is prescribed for the treatment of acute rheumatism, rheumatoid polyarthritis, ankylosing spondylitis (Ankylosing spondylitis– a chronic inflammatory disease of the joints and joints of the spine, especially the sacroiliac, intervertebral joints, costovertebral joints and joints of the vertebral processes, which tends to ankylosis (immobility of the joints)). Used for headaches, toothaches, arthralgia, myalgia (Myalgia- muscle pain caused by spasm, compression, inflammation or muscle ischemia), fever (Fever– a special reaction of the body that accompanies many diseases and is manifested by an increase in body temperature. A febrile reaction most often occurs when infectious diseases, with the introduction of therapeutic serums and vaccines, with traumatic injuries, crushed tissue, etc.), infectious-allergic myocarditis (Myocarditis– inflammatory disease of the heart muscle of an infectious, allergic or toxic-allergic nature), dysmenorrhea (Dysmenorrhea- a cyclical pathological process in which severe pain in the lower abdomen appears on the days of menstruation. These pains may be accompanied by other symptoms: general weakness, nausea, vomiting, headache, dizziness, lack of appetite, dry mouth, drooling, bloating, etc.), premenstrual syndrome (Premenstrual syndrome (premenstrual tension syndrome) - a cyclical change in the mood and physical condition of a woman, occurring 2-3 days or more before menstruation, disrupting the usual way of life or work and alternating with a period of remission associated with the onset of menstruation, lasting at least 7-12 days), acute respiratory (Respiratory- respiratory, pertaining to breathing) viral infections and influenza.

Directions for use and doses

Mefenamic acid-Darnitsa is taken orally after meals (it is recommended to take it with milk).
Adults and children over 14 years of age are prescribed 0.25-0.5 g 3-4 times a day.
If necessary, the daily dose can be increased to 3 g per day.
After achieving a therapeutic effect, the daily dose is reduced to 1 g.
Children aged 5 to 14 years are prescribed 0.25 g 3-4 times a day.
The duration of the course of treatment is 20-45 days (if necessary - 2 months or more).

Side effect

Nausea, heartburn, diarrhea (Diarrhea- frequent discharge of liquid feces, associated with accelerated passage of intestinal contents due to increased peristalsis, impaired absorption of water in the large intestine and the release of a significant amount of inflammatory secretion by the intestinal wall), abdominal pain, anorexia, flatulence (Flatulence- accumulation of gases in the digestive tract with bloating, rumbling, belching, cramping pain), gastrointestinal bleeding, constipation, general weakness, drowsiness, irritability, insomnia, visual disturbances, albuminuria, allergic reactions ( itching (Itching- a modified feeling of pain caused by irritation of the nerve endings of pain receptors), edema (Edema– tissue swelling as a result of a pathological increase in the volume of interstitial fluid) face, rash, etc.). With prolonged use (2 months or more) may develop hemolytic anemia (Hemolytic anemia– anemia caused by increased hemolysis (destruction of red blood cells), which occurs due to a defect in the structure of red blood cell membranes), decrease in hematocrit, hematopoietic disorders. When the concentration of the drug in the blood is 100-200 mcg/l or higher, muscle twitching, convulsions, and vomiting may be observed.

Contraindications

Peptic ulcer of the stomach and duodenum, inflammatory diseases of the digestive tract, diseases of the kidneys and hematopoietic organs.

Overdose

In case of an overdose, muscle twitching, convulsions, vomiting, and breathing problems may occur.

Features of application

Mefenamic acid-Darnitsa may cause negative influence on the cardiovascular system of the fetus, therefore its use in pregnant women is not recommended.
The drug is able to penetrate into breast milk, therefore its use during the period lactation (Lactation- secretion of milk from the mammary gland) should be limited.
Caution is required when using the drug in persons with impaired renal function, in patients with bronchial asthma, as well as in persons with a history of gastric and duodenal ulcers.

Interaction with other drugs

When used simultaneously with analgin, the anti-inflammatory effect of Mefenamic acid-Darnitsa increases. Concomitant use with other non-steroidal anti-inflammatory drugs increases the likelihood of side effects from the gastrointestinal tract.
Thiamine, pyridoxine hydrochloride, barbiturates, phenothiazine derivatives, narcotics analgesics (Analgesics- medications that relieve or eliminate pain. Opium preparations, its alkaloids, and their synthetic substitutes are called narcotic analgesics; analgin, paracetamol, acetylsalicylic acid, etc. - non-narcotic analgesics), caffeine, diphenhydramine increase the analgesic effect of the drug. Mefenamic acid-Darnitsa increases activity oral (Orally- route of administration of the drug through the mouth (per os)) anticoagulants.

General Product Information

Conditions and shelf life. Store in a dry place, protected from light and out of reach of children. Shelf life - 5 years.

Vacation conditions. Over the counter.

Package. 10 tablets per blister pack.

Manufacturer.CJSC "Pharmaceutical Firm "Darnitsa".

Location. 02093, Ukraine, Kyiv, st. Boryspilskaya, 13.

Website. www.darnitsa.ua

This material is presented in free form on the basis of the official instructions for medical use of the drug.

Dosage form

Pills.

Basic physical and chemical properties: tablets are grayish-white in color with a slightly yellowish or greenish tint, flat-cylindrical in shape, with a chamfer and a score, marbling is allowed.

Pharmacological group

Nonsteroidal anti-inflammatory and antirheumatic drugs. Fenamata.

ATX code M01A G01.

Pharmacological properties

Pharmacodynamics.

Mefenamic acid is a non-steroidal anti-inflammatory drug. The mechanism of anti-inflammatory action is due to the ability to inhibit the synthesis of inflammatory mediators (prostaglandins, serotonin, kinins, etc.), reduce the activity of lysosomal enzymes that take part in the inflammatory reaction. Mefenamic acid stabilizes protein ultrastructures and cell membranes, reduces vascular permeability, disrupts oxidative phosphorylation processes, inhibits the synthesis of mucopolysaccharides, inhibits cell proliferation at the site of inflammation, increases cell resistance and stimulates wound healing. Antipyretic properties are associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center.

Mefenamic acid stimulates the formation of interferon.

In the mechanism of analgesic action, along with the influence on the central mechanisms of pain sensitivity, a significant role is played by the local effect on the site of inflammation and the ability to inhibit the formation of algogens (kinins, histamine, serotonin).

Pharmacokinetics.

After oral administration, mefenamic acid is quickly and fairly completely absorbed from the digestive tract. The maximum concentration in the blood is observed 2 to 4 hours after administration. The blood level is proportional to the dose. The equilibrium concentration (20 mcg/ml) is determined on the 2nd day of use (1 g 4 times a day). Binds 90% to blood albumin. In the liver it forms metabolites by oxidation, hydrolysis, glucuronidation. The half-life (T 1/2) is 2 – 4 hours. It is excreted from the body unchanged and in the form of metabolites mainly by the kidneys (67% of the dose), with feces (20–25%).

Indications

Acute respiratory viral infections and influenza.

Pain of low and moderate intensity: muscle, joint, traumatic, dental, headache different etiologies, postoperative and postpartum pain.

Primary dysmenorrhea. Dysfunctional menorrhagia, including those caused by the presence of intrauterine contraceptives, in the absence of pathology of the pelvic organs.

Inflammatory diseases of the musculoskeletal system: rheumatoid arthritis, rheumatism, ankylosing spondylitis.

Contraindications

Hypersensitivity to the components of the drug. Bronchospasm, Quincke's edema, rhinitis, bronchial asthma or a history of urticaria that occurred after use acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Simultaneous administration of specific COX-2 inhibitors. Peptic ulcer of the stomach and duodenum, including a history of inflammatory bowel disease, diseases of the hematopoietic organs, severe heart failure, severe liver or kidney dysfunction, gastrointestinal bleeding or perforation caused by taking non-steroidal anti-inflammatory drugs.

Interaction with other drugs and other types of interactions

Thiamine, pyridoxine hydrochloride, barbiturates, phenothiazine derivatives, narcotic analgesics, caffeine, diphenhydramine increase the analgesic effect of the drug.
At joint use mefenamic acid and methotrexate the toxic effects of methotrexate are enhanced.

Antihypertensive drugs (ACE inhibitors and angiotensin II receptor antagonists): decreased antihypertensive effect, increased risk of renal failure, especially in elderly patients. Patients should drink enough fluids. It is also necessary to assess renal function at the beginning of treatment and during concomitant therapy.

Diuretics: decreased diuretic effect. Diuretics may increase the nephrotoxicity of NSAIDs.

Cardiac glycosides: NSAIDs may worsen heart failure, reduce glomerular filtration rate and increase plasma levels of cardiac glycosides.
Cyclosporine: increased risk of developing nephrotoxicity.

Mifepristone: NSAIDs should not be taken for 8 to 12 days after taking mifepristone - NSAIDs may reduce the effects of mifepristone.

Corticosteroids: increased risk of developing gastrointestinal ulcers and bleeding.

Antiplatelet agents and selective inhibitors recapture serotonin: increased risk of gastrointestinal bleeding.

Fluoroquinolones: NSAIDs increase the risk of seizures.

Aminoglycosides: NSAIDs increase the risk of nephrotoxicity.

Tacrolimus: there may be an increased risk of developing a nephrotoxic effect.

Zidovudine: NSAIDs increase the risk of hematological toxicity. The risk of joint hemorrhage and hematoma increases in HIV-positive hemophiliacs who are simultaneously treated with zidovudine.

Lithium preparations: decreased lithium excretion and increased risk of lithium toxicity.
Mefenamic acid increases activity oral anticoagulants, therefore, their simultaneous use increases the risk of bleeding. Concomitant use of mefenamic acid with oral anticoagulants requires careful monitoring of prothrombin time. NSAIDs should be used with extreme caution with warfarin or heparin - medical supervision is required.

Simultaneous use with other non-steroidal anti-inflammatory drugs increases the anti-inflammatory effect and the likelihood of side effects from the gastrointestinal tract.

Application Features

The drug is prescribed with caution to patients with acute cardiovascular failure, arterial hypertension, and coronary heart disease.

The drug is prescribed with caution to patients with epilepsy.

Mefenamic acid should not be used in patients who have previously experienced hypersensitivity reactions, such as asthma, bronchospasm, rhinitis, angioedema or urticaria.

Do not use in dehydrated patients who have lost fluid due to vomiting, diarrhea, or increased urination.

For long-term treatment of headaches, you should consult your doctor.

At moderate violations liver or kidney function there are no special recommendations for the use of the drug.

NSAIDs should be taken with caution in patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn's disease), since exacerbation of the disease is possible. If the use of mefenamic acid leads to gastrointestinal bleeding and perforation, treatment should be discontinued.

Elderly patients usually have an increased risk of developing side effects from the gastrointestinal tract, especially gastrointestinal bleeding and perforation, which can be fatal, so treatment should be started with the lowest dosage.

Patients with systemic lupus erythematosus and mixed connective tissue diseases are at increased risk of aseptic meningitis.

Mefenamic acid should be used with caution in patients at high risk of serious skin reactions, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Mefenamic acid should be discontinued at the first appearance of skin rash, mucosal damage, or any other manifestation of hypersensitivity.

With long-term use of the drug, it is necessary to monitor blood counts, since mefenamic acid can cause pathological changes from the blood side. If manifestations of any dyscrasia occur, drug therapy should be discontinued.

Taking mefenamic acid may cause gastrointestinal problems (eg diarrhea). They can occur either immediately after using the drug or after long-term use. If such symptoms occur, you must stop using the drug.

Caution should be exercised when using mefenamic acid in patients receiving therapy with drugs that increase the risk of bleeding: corticosteroids, anticoagulants (warfarin) and aspirin.

Taking mefenamic acid may impair female fertility and is not recommended for women who are trying to become pregnant. When used by women with symptoms of dysmenorrhea and menorrhagia and the absence of a therapeutic effect, it is necessary to consult a doctor.

Use during pregnancy or breastfeeding

The drug is not used by women during pregnancy or breastfeeding.

The ability to influence the reaction rate when driving vehicles or other mechanisms

Care should be taken when driving vehicles or operating machinery that requires increased attention, since sometimes the use of the drug can cause drowsiness, blurred vision, and convulsions.

Directions for use and doses

The drug should be used under the supervision of a doctor, who determines the dose and duration of treatment. Use internally. The medicine should be taken after meals with milk.

Adults and children over 12 years old Prescribe 250–500 mg 3–4 times a day. According to indications and if well tolerated, the daily dose is increased to a maximum of 3000 mg; after achieving a therapeutic effect, the dose is reduced to 1000 mg/day.

Children aged 5 to 12 years– 250 mg 3 – 4 times a day.

The course of treatment for joint diseases can last from 20 days to 2 months or more. When treating pain syndrome, the course of treatment lasts up to 7 days.

Children

The drug is contraindicated in children under 5 years of age.

Overdose

Symptoms: pain in the epigastric region, nausea, vomiting, drowsiness. In severe cases - gastrointestinal bleeding, respiratory depression, arterial hypertension, twitching of individual muscle groups, coma.

Treatment. There is no specific antidote. Gastric lavage with suspension activated carbon. Alkalinization of urine, forced diuresis. Symptomatic therapy. Hemosorption and hemodialysis are ineffective due to the strong binding of mefenamic acid to blood proteins.

Side effects

From the organs of vision: blurred vision, reversible loss of color vision, eye irritation.

From the organs of hearing and vestibular apparatus: ringing in the ears, otalgia.

From the respiratory system, organs chest and mediastinum: dyspnea, bronchospasm.

From the gastrointestinal tract: epigastric pain, anorexia, heartburn, nausea, flatulence, vomiting, enterocolitis, colitis, exacerbation of colitis and Crohn's disease, gastritis, hepatotoxicity, steatorrhea, cholestatic jaundice, hepatitis, pancreatitis, hepatorenal syndrome, hemorrhagic gastritis, peptic ulcer with or without bleeding him. Gastrointestinal bleeding, perforation or gastrointestinal bleeding, sometimes fatal, especially in elderly patients, dyspepsia, constipation, diarrhea.

From the kidneys and urinary system: dysuria, cystitis. Renal dysfunction, albuminuria, hematuria, oliguria or polyuria, renal failure, including papillary necrosis, acute interstitial nephritis, nephrotic syndrome, allergic glomerulonephritis, hyponatremia, hyperkalemia.

From the outside nervous system: drowsiness or insomnia, weakness, irritability, agitation, headache, blurred vision, convulsions, optic neuritis, paresthesia, dizziness, stiff neck, fever, disorientation. From the mental side: confusion, depression, hallucinations.

From the cardiovascular system: arterial hypertension, arrhythmia, rarely - congestive heart failure, peripheral edema, fainting, arterial hypotension, palpitations, shortness of breath, thrombotic complications (for example, myocardial infarction or stroke).

From the blood and lymphatic system: aplastic anemia, autoimmune hemolytic anemia, prolongation of bleeding time, eosinophilia, leukopenia, thrombocytopenia, decreased hematocrit, thrombocytopenic purpura, agranulocytosis, neutropenia, pancytopenia, bone marrow hypoplasia.

From the immune system: hypersensitivity reactions, including skin rashes, itching, facial swelling, allergic rhinitis, angioedema, laryngeal edema, Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme, urticaria, bullous pemphigus, photosensitivity, asthma, anaphylaxis.

From the skin and subcutaneous tissue: purpura, skin rashes, itching, erythema multiforme, urticaria, bullous pemphigus.

Laboratory indicators: impaired glucose tolerance in patients diabetes mellitus, a positive reaction in some tests for the presence of mefenamic acid and its metabolites in bile and urine. Increased levels of liver enzymes in blood plasma.

Other: aseptic meningitis, sweating, increased fatigue, malaise, multiple organ failure, hyperthermia.

Best before date

Storage conditions

Store out of the reach of children in the original packaging at a temperature not exceeding 25 °C.

Package

10 tablets in a blister pack; 2 blister packs per pack.

Mefenamic acid has anti-inflammatory and antipyretic properties. It helps reduce the inflammatory process. This drug improves wound healing. The antipyretic effect of the drug is explained by the fact that Mefenamic acid reduces the production of prostaglandins. The product has an antiviral effect because it improves the process of interferon formation.

In what cases should it be used?

Mefenamic acid is used for inflammatory joint diseases. The drug reduces swelling and relieves inflammation. It can be used for rheumatism and arthritis. The duration of course treatment for joint pathologies can reach two months. Mefenamic acid is effective in the complex treatment of influenza and viral infections.

The medication will help with female problems: it should be used for dysfunctional dysmenorrhea and prolonged uterine bleeding. The drug can be taken for headaches, muscle pain, and postoperative pain.

What dosages are provided?

Mefenamic acid should be taken orally after meals. The medicine should be taken with milk. Children over 12 years of age should drink 250–500 mg of the drug three times a day. The maximum daily dosage is 3000 mg. When positive dynamics are achieved, the dose is reduced to 1000 mg. Children aged five to twelve years should take 250 mg of mefanamic acid no more than four times a day. The duration of treatment is about a month. When therapeutically treating a pain symptom, the drug must be used for at least a week.

What can you say about side effects?

Mefenamic acid causes adverse changes in the body's digestive system. Often when using the drug, abdominal pain, diarrhea and nausea occur. The drug can cause internal bleeding, stomach ulcers, and pancreatitis. It often increases the level of liver enzymes in the blood. Acid also affects the body’s hematopoietic system: it can lead to anemia and thrombocytopenia. This medication may increase arterial pressure, changes in heart rate. In rare cases, after taking the medicine, heart failure develops and edema appears.

The acid can cause bronchial spasms and an allergic reaction. It worsens the condition of the kidneys and nervous system. When taking the medicine, the patient's sleep is often disturbed and he becomes irritable. The drug has a negative effect on the senses: when taking this medication, you may experience tinnitus, vision problems, and eye inflammation.

Who is this medicine contraindicated for?

In some cases this medication should not be used:

• Mefenamic acid should not be taken if you are hypersensitive to the components of the product.
• This medicine is prohibited for use in cases of gastric ulcers and inflammatory processes in the intestines.
• It should not be prescribed for severe blood diseases, serious pathologies of the liver and kidneys.
• Children under five years of age should not take this medicine.
• The drug should not be used during pregnancy or breastfeeding. The medicine increases the heart rate of the unborn baby.
• The medication should not be taken by women who are planning a pregnancy in the near future, since after its use problems with conception may appear.

Be careful!

This medicine has a large number of side effects. When treating with this drug, you must exercise caution:

• This medication should not be used by people who have had heart surgery.
• The use of this medication is not recommended if you are allergic to Aspirin.
• Elderly patients may experience adverse complications during treatment.
• The risk group also includes patients with diabetes, epilepsy, and angina pectoris. Such patients need to reduce the recommended dosage of the drug.
• If a person has systemic lupus erythematosus, taking the drug is not recommended due to the high likelihood of meningitis.
• Treatment should be stopped if skin rash and diarrhea appear. At long-term use medications, it is necessary to monitor blood parameters and kidney function.
• This medication dulls the body's natural reaction; when treating with this drug, you need to be careful when operating a car.

Doctor Komarovsky's opinion

A well-known pediatrician does not recommend using Mefenamic acid in the treatment of children. The pediatrician believes that this medicine is highly effective and quickly reduces fever. But the drug contains a large amount harmful substances, therefore in many developed countries refused to use this drug as an antipyretic.

Komarovsky writes that to reduce the temperature it is better to use Paracetamol and Ibuprofen. These medicines meet all the necessary requirements. They are effective and suitable for treating young patients.

How to use medicinal paste correctly?

Pasta and medicinal solution Supplements containing mefenamic acid must be used within a few days, so they should be prepared before use. The paste is used to relieve toothache. The therapeutic course involves at least seven sessions. For ulcers on the oral mucosa, applications are made using an aqueous solution of the product. Such procedures should be carried out up to two times a day.

Useful product based on Mefenamic acid

In addition to this acid, Mephenate ointment contains vilinin. It has a bacteriostatic effect. Vilinin is effective for wound healing. It can be used for trophic ulcers, purulent wounds, burns. This tool It is also prescribed for eczema, boils, and severe cracks in the lips.

The structure of the ointment also contains polyethylene oxide. It reduces inflammation and promotes deep penetration ointments into the skin.

The ointment has a local effect, it gives a long-lasting effect. The average duration of action is 10 hours.

The product should be applied to the affected part of the body using a gauze pad twice a day. The product has a slight analgesic effect. The duration of treatment is about 14 days. Sometimes there is irritation in the area where the ointment was applied. The redness usually goes away after a few days.

How does the drug interact with other drugs?

If you use this drug in parallel with taking Analgin, the inflammatory process in the patient will go away much faster. It is not recommended to take other non-steroidal anti-inflammatory drugs. Some doctors believe that in the treatment of acute respiratory diseases, in addition to Mefenamic acid, Immusstat should be used. As research results have shown, these two drugs interact well with each other: they quickly eliminate the unpleasant manifestations of the disease and reduce the likelihood of complications.

Mefenamic acid is a fairly serious medicine, so you should consult your doctor before starting a course of treatment. Under no circumstances should you exceed the recommended dosage of the drug!

The following two tabs change content below.

One of the most unpleasant symptoms accompanying most diseases is pain. If the pain becomes unbearable, then both inflammation and swelling are present. Mefenamic acid can cope with these unpleasant symptoms. This drug is used not only to eliminate the symptoms of the disease, but also in the treatment of ulcers and inflammation of the musculoskeletal system.

____________________________

Composition and properties

Mefenamic acid is available in the form of tablets, which include:

The active substance is mefenamic acid.

Mefenamic acid belongs to non-steroidal anti-inflammatory and antirheumatic drugs, and has the following properties:

Excipients – methylcellulose; starch; magnesium stearate; croscarmellose sodium; ocatdecanoic acid.

Indications and contraindications

Indications for the use of mefenamic acid are the following diseases or disorders:

In addition, the drug is used as an antipyretic for fevers. If a woman plans to become pregnant, she should avoid using the drug as it may impair fertility.

Contraindications to the use of mefenamic acid are:

• Pregnancy and breastfeeding.
• Children under five years of age.
• Blood diseases.
• Peptic ulcer of the stomach and duodenum.
• Inflammatory processes of the gastrointestinal tract.
• Impaired kidney and liver function.
• Gastritis.
• Cirrhosis of the liver.
• Heart failure.
• Allergic reaction to a component of the drug.

Mefenamic acid reduces the reaction rate, so it is not recommended to drive while taking it. The drug should be prescribed with caution to patients with epilepsy or heart disease.

Instructions for use

The method of administration and dosage of Mefenamic acid depends on the age of the patient:

To reduce possible irritation of the gastric mucosa, the drug can be taken with meals.

Overdose, adverse reactions

In case of accidental overdose of the drug, the following symptoms may occur, in which case you should immediately consult a doctor:

Treatment includes symptomatic therapy, forced diuresis, and gastric lavage. Mefenamic acid binds tightly to blood proteins, so hemodialysis is not effective.

In addition to overdose, a possible rare manifestation adverse reactions for the drug:

• Discomfort in the gastrointestinal tract.
• Pain in the intestines and stomach.
• Gastrointestinal bleeding.
• Rarely development of ulcers.
• Purpura.
• Edema.
• Heart rhythm disturbances.
• Increased blood pressure.
• Dysuric manifestations.
• Renal dysfunction.
• Agranulocytosis.
• Eosinophilia.
• Hematuria.
• Irritability.
• Sleep disorders.
• Skin rash.
• Hives.

If any adverse reactions occur, do not make a decision on your own; it is important to immediately consult a doctor or call emergency help.

Video